Chronic Lymphocytic Leukemia | Specialty

The chronic lymphocytic leukemia condition center is a comprehensive resource for clinical news on chronic lymphocytic leukemia. Read more at OncLive.

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL

April 4th 2025

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Dr Alencar on Unmet Needs Associated With BTK Inhibitor Resistance in CLL

March 17th 2025

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

HCP Survey Outlines Challenges, Strategies for Venetoclax Initiation in CLL in the Community Setting

March 12th 2025

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax

March 10th 2025

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes

March 10th 2025

On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes.

Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL

March 6th 2025

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression

March 6th 2025

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

Combination Regimens Expand CLL Treatment Paradigm

March 4th 2025

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL

March 3rd 2025

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

February 28th 2025

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

February 24th 2025

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL

February 24th 2025

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

February 21st 2025

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

February 19th 2025

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Reflections and Future Directions in CLL Management

February 17th 2025

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Emerging Agents and Future Strategies in Relapsed/Refractory CLL

February 17th 2025

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Venetoclax Plus Obinutuzumab Improves MRD Clearance in Previously Untreated CLL

February 10th 2025

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.